7,562.50

-12.00

-0.16%

51,916.00

-217.00

-0.42%

28,122.75

-4.75

-0.02%

Russell 2000 Futures

2,813.70

-4.10

-0.15%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,933.90

-35.70

-0.90%

76,576.91

-1,672.06

-2.14%

Crude Oil Dec 26

97.22

+0.76

+0.79%

US Private Equity

10,836.30

-14.33

-0.13%

OTC Markets OTCPK - Delayed Quote USD

Immutep Limited (PRRUF)

0.0168 -0.0032 (-16.00%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for PRRUF

Chart Range Bar

Interval:

In partnership with ChartIQ

Immutep Quarterly Activities Report Q1 FY27

Immutep Quarterly Activities Report Q1 FY27

Immutep Receives A$2.16 million French R&D Tax Incentive

Immutep Receives A$2.16 million French R&D Tax Incentive

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Change to American Depositary Share Ratio

Change to American Depositary Share Ratio

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Immutep Quarterly Activities Report Q4 FY26

Immutep Quarterly Activities Report Q4 FY26

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: